At a glance
ClinicalIndex Comparison RecordN/AUnknown· 394 enrolled
Drug / intervention
Metformin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
In Brief
An observational study evaluating Metformin and Placebo for Breast Cancer and 3 related conditions. Targeting 394 participants across 256 sites in 2 countries.
Detailed Summary
RATIONALE: Studying samples of blood in the laboratory from patients with breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to fatigue. PURPOSE: This research study is studying biomarkers associated with fatigue in patients with early-stage breast cancer treated with metformin or placebo on NCIC-CTG-MA.32.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Depression, Fatigue, Sleep Disorders
CountriesCanada, United States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/AUnknownOverdue
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2011
Enrollment StartJul 2011
Primary CompletionSep 2016
TodayJul 2026
First PostedJan 31, 2011
Enrollment StartJul 1, 2011
Primary CompletionSep 1, 2016
TodayJul 1, 2026
Enrollment to primary: 5.2 yearsPosted 15.4 years ago
Interventions
Metformindrug
Placebodrug